Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer

PLoS ONE(2023)10.1371/journal.pone.0280507Source: DataRank Database

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer is a research paper published in PLoS ONE (2023). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.80)OA: goldTopics (60)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Mads H. Haugen ORCID,Vesa Hongisto ORCID,Miriam R. R. Aure ORCID,Suvi‐Katri Leivonen ORCID,Vessela N. Kristensen ORCID

Live enrichment

PubMed:36706086 PMC:PMC9882887 OpenAlex:https://openalex.org/W4318250039

Helse Sør-Øst RHF

Grant: 2017034

Helse Sør-Øst RHF

Grant: 2019081

NCI

Grant: CA16672

NIH

Grant: R50CA221675

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

Grant: 5R50CA221675-02

Functional Proteomics by Reverse Phase Protein Array in Cancer

FWCI

0.80

Citation Percentile

0.7%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0280507&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0280507&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0280507

journalhttps://doi.org/10.1371/journal.pone.0280507

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36706086

Fields of Study

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchChronic Lymphocytic Leukemia Research03 medical and health sciences0302 clinical medicine

MeSH Terms

TrastuzumabDasatinibLapatinibAntineoplastic AgentsBreast NeoplasmsFemaleHumansQuinazolinesReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesCell Line, TumorAntibodies, Monoclonal, Humanized

Keywords

DasatinibBreast cancerCancerThroughputMedicineCancer researchIn vitroPharmacologyOncologyBioinformaticsComputational biologyBiologyInternal medicineComputer scienceImatinibGeneticsScience610ActivationBreast NeoplasmsAntineoplastic AgentsDiscoveryAntibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine KinasesGrowth-factor receptorCell Line, TumorChemotherapyHumansTrastuzumab resistanceSingle-agentTucatinibBiochemistry, cell and molecular biologyKinase inhibitorQRLapatinibTrastuzumabBiomedicineContributesAntitumor-activityQuinazolinesFemaleResearch Article

Sustainable Development Goals

SDG 0: Good health and well-being

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer

FAIR Checklist

Authors (10)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)